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Abstract
Purpose/Objectives: The clinical effects of radiation dose-intensification in locally advanced non-small cell lung
(NSCLCa) and other cancers are challenging to predict and are ideally studied in randomized trials. The purpose of
this study was to assess the use of dose-escalated radiation for locally advanced NSCLCa in the U.S., 2004–2013, a
period in which there were no published level 1 studies on dose-escalation.
Materials/Methods: We performed analyses on two cancer registry databases with complementary strengths and
weaknesses: the National Oncology Data Alliance (NODA) 2004–2013 and the National Cancer Database (NCDB)
2004–2012. We classified locally advanced patients according to the use of dose-escalation (>70 Gy). We used
adjusted logistic regression to assess the association of year of treatment with dose-escalated radiation use in two
periods representing time before and after the closure of a cooperative group trial (RTOG 0617) on dose-escalation:
2004–2010 and 2010–2013. To determine the year in which a significant change in dose could have been detected
had dose been prospectively monitored within the NODA network, we compared the average annual radiation
dose per year with the forecasted dose (average of the prior 3 years) adjusted for patient age and comorbidities.
Results: Within both the NODA and NCDB, use of dose-escalation increased from 2004 to 2010 (p < 0.0001) and
decreased from 2010 to 2013 (p = 0.0018), even after controlling for potential confounders. Had the NODA network
been monitoring radiation dose in this cohort, significant changes in average annual dose would have been
detected at the end of 2008 and 2012.
Conclusions: Patterns of radiation dosing in locally advanced NSCLCa changed in the U.S. in the absence of
level 1 evidence. Monitoring radiation dose is feasible using an existing national cancer registry data
collection infrastructure.
Introduction
Incremental technical advances in linear accelerators
have steadily improved the delivery of radiotherapy to a
patient’s tumor while sparing the adjacent normal tissue.
Leveraging advances in technology to dose-intensify is
compelling particularly in diseases for which local
control outcomes are poor, such as inoperable locally
advanced non-small cell lung cancer (NSCLCa) which
has an estimated 2-year local failure rate of 30% when
treated with concurrent chemotherapy and standard
dose radiation [1]. However, the clinical effects of dose-
intensification in NSCLCa and other cancers have been
challenging to predict and several clinical studies have
failed to validate presumed benefits [1–3]. A recent
example is RTOG 0617 which randomized inoperable
locally advanced NSCLCa patients to 60 Gy (standard
arm) or 74 Gy (dose-escalation arm) with concurrent
chemotherapy [4]. Unexpectedly, patients treated on the
dose-escalation arm had substantially worse median
overall survival (20.3 months versus 28.7 months), des-
pite having acceptable radiation treatment plans based
on established normal tissue constraints.
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We hypothesized that because the theoretical rationale
for dose-intensified treatments are compelling, they are
slowly adopted even in the absence of high level clinical
evidence and that this “radiation dose creep” may unex-
pectedly be causing harm. To assess the first of these
hypotheses, that radiation dose creep occurs, we evalu-
ated the patterns of radiation dosing in locally advanced
NSCLCa between 2004 and 2013, a period in which
there were no published level 1 studies on dose-
escalation. We hypothesized that there would be an
increasing trend in the use of dose-escalated radiation in
the years preceding the closure of RTOG 0617 and that
there would be a decreasing trend beginning immedi-
ately preceding the study’s closure to the end of the
study period.
Finally, we sought to determine the year in which a
significant change in radiation dosing practice patterns
could have been detected in this study period had dose




The primary analyses of this study were performed on
data extracted from two cancer registry databases with
complementary strengths and weaknesses: the National
Oncology Data Alliance® (NODA) (Elekta Inc., Sunnyvale,
CA), years 2004–2013, and the National Cancer Database
(NCDB) (American College of Surgeons, Chicago, Il),
years 2004–2012. The NODA captures newly diagnosed
cancer cases at more than 150 hospitals in the U.S. and
includes all of the data fields sent to state and federal
cancer registries. The strength of the NODA is that it
includes radiation dose fields that are assessed for internal
validity by reviewers with specialized radiation oncol-
ogy training. The NODA, however, may not be broadly
representative of U.S. practice. To assess the gene-
ralizability of our observations, we performed the same
analysis using data from the NCDB, a more representa-
tive database that captures information from approxi-
mately 70% of all newly diagnosed cancers in the U.S.
[5]. A weakness of the NCDB is that radiation dose is
not secondarily validated. Both the NODA and the
NCDB require a minimum set of database fields to be
completed by registrars to meet submission require-
ments, so every case of locally advanced NSCLCa
treated at participating institutions is not necessarily
captured within these databases.
Cohort identification
To minimize confounding, we sought to restrict our
patterns of care analysis to patients likely meeting eligi-
bility criteria for RTOG 0617 since this represents a
cohort deemed potentially suitable for dose-escalated
radiation by subject matter experts in the era of interest.
Using manual chart review as the gold standard, we
iteratively developed a cancer registry-based algorithm
that classifies patients based on RTOG 0617 eligibility
and whether they were treated with definitive-intent
concurrent chemotherapy and radiation. To minimize
misclassification errors, the algorithm was more restrict-
ive than RTOG 0617 eligibility criteria with respect to
tumor staging and prior allowable malignancies. The
study cohorts included only patients with AJCC versions
6 and 7 clinical T3, N1 or T0-3, N2, M0, but excluded
patients with derived AJCC v6 stage IIB, which included
Table 1 Patient and hospital characteristics before and after
1/1/2011. The closure of the high dose arms of RTOG 0617 was








No. (%) No. (%)
Age
≤ 67 yo 663 (51.4) 230 (51.9) 0.85
> 67 yo 627 (48.6) 213 (48.1)
Sex
Male 750 (58.1) 269 (60.7) 0.91
Female 540 (41.9) 174 (39.3)
Race
White 1127 (87.4) 375 (84.6) 0.12
Non-white 152 (11.8) 68 (14.7)
Missing 11 (0.8) 3 (0.7)
Histology
Squamous 519 (40.2) 226 (51.0) <0.0001
Non-Squamous 771 (59.8) 217 (49.0)
Derived AJCC v6 T-stagea
T0-2 862 (66.8) 292 (65.9) 0.42
T3 392 (30.4) 146 (33.0)
Missing 36 (2.8) 5 (1.1)
Charlson/Deyo Score
0 863 (66.9) 195 (60.7) 0.04
1 319 (24.7) 96 (28.0)
2+ 108 (8.4) 34 (11.3)
Hospital type
Community 1047 (81.2) 374 (84.4) 0.12
Academic 243 (18.8) 69 (15.6)
Hospital setting
Metro 1065 (82.6) 378 (85.3) 0.17
Non-metro 225 (17.4) 65 (14.7)
*Chi-square tests; missing data was excluded from comparisons. aT–stage
comparison was done only for patients staged according to AJCC version 6.
Hospital characteristics are those of the diagnosing hospital, not treating institution
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clinical T2, N1, and M0. The algorithm excluded
patients treated to total doses of <59 Gy (to omit
patients who received pre-operative radiation or pallia-
tive radiation or who discontinued radiation early) and pa-
tients with total doses of >80 Gy (to omit outliers likely
related to reporting errors). We assessed the algorithm’s
ability to predict RTOG 0617 eligibility (positive predictive
value) in validation cohorts at cancer registry programs in
two regionally distinct hospitals.
Internal and external validity
To assess internal validity (e.g., confounding and bias)
within the NODA cohort, we used chi-square tests to
compare the distribution of covariates between patients
treated in the years before (2004–2010) and after (2011–
2013) the early closure of RTOG 0617 (on June 17,
2011). We evaluated the external validity (e.g.,
generalizability) of our NODA findings in two ways.
First, we used chi-square tests to compare the distribu-
tion of patient covariates in the NODA cohort (exclud-
ing 2013 cases) and the NCDB 2004–2012 cohort. In
order to maximize the representativeness of the NCDB,
we did not filter the NCDB cohort on radiation dose
(unfiltered NCDB 2004–2012) for this first gene-
ralizability analysis. Second, after our a priori hypotheses
were confirmed in the NODA cohort, we determined
whether these patterns were also present in the NCDB,
2004–2012, which was similarly filtered on radiation
dose (filtered NCDB 2004–2012).
Primary outcome and control variables
The primary outcome was the use of dose-escalated
radiation over two a priori-defined periods. Period 1
was defined from 1/1/2004 to 12/31/2010, the period
before the early closure of the high dose arms of RTOG
0617 was announced to participating institutions.
Period 2 was defined from 1/1/2010 to 12/31/2013,
which is the period immediately before RTOG 0617
closure through the data collection period. We defined
dose-escalated radiation as a total dose of >70 Gy,
consistent with guidelines and on-going national trials
[6, 7]. Both NODA and NCDB capture delivered dose,
not prescribed dose. We a priori selected patient and
disease control variables that might affect a physician’s
perception of the tolerability and effectiveness of dose-
escalated radiation and characteristics of the diagnosing
hospital that might affect patterns of care (Table 1).
Characteristics of the diagnosing hospital were defined
as previously described [8, 9]. We calculated confidence
intervals around the estimated annual percentage of pa-
tients treated with dose-escalated radiation using the
Clopper-Pearson method. We used logistic regression
to assess the covariate-adjusted association of the year
of treatment (continuous variable) with dose-escalated
radiation use (categorical variable) and in each period
of interest. In a post hoc analysis, we characterized
the use of total doses in the ‘low-standard dose’ range
(≥59 Gy and <64 Gy), a dose most consistent with the
superior arm of RTOG 0617.
Fig. 1 The NODA (a) and the NCDB (b) cohorts and reasons for exclusions. Abbreviations: chemo, chemotherapy; RT, radiation; Gy, Gray
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We used linear regression to determine the year in
which a significant change in radiation dosing could
have been detected had total radiation dose been pro-
spectively monitored within the NODA network. We
compared the actual average radiation dose (continuous
variable) used for a given year across the network with
a forecasted average dose based on the average of the
prior three years, with adjustments for age and comor-
bidities. For 2005 and 2006, where three years of prior
data were not available, we forecasted based on the
prior year and two years, respectively.
Statistical significance was set a priori at 0.01 because
multiple hypotheses were being tested. Missing values
were uncommon so were excluded from statistical
analyses.
Results
The positive predictive values for the RTOG 0617 eli-
gibility algorithm were 90.2% (37/41 patients) and
91.2% (31/34) based on manual chart review at the
first and second cancer registry programs, respect-
ively. The most common reason for false positives
within both validation sets was failure to meet RTOG
0617 performance status and pulmonary function test
criteria. The positive predictive values of the algo-
rithm with respect to total radiation dose were 97.5%
(40/41) and 97.1% (33/34) at the first and second
cancer registry programs, respectively.
When applied to the NODA dataset, the algorithm iden-
tified 1733 patients treated between 2004 and 2013, of
whom 499 (29%) patients were treated with dose-
escalated radiation (Fig. 1). Table 1 shows the distribu-
tion of patient, disease and hospital factors in the
period from 2004 to 2010 versus 2011–2013. The
patients treated in 2004–2010 and 2011–2013 were
similar with respect to age, sex, race, T-stage and diag-
nosing hospital academic status and metropolitan sta-
tus. Table 2 shows a comparison of the distribution of
patient, disease and contextual variables of the NODA
primary analytic cohort (excluding 2013 data) and the
NCDB 2004–2012 NSCLCa cohort without radiation
dose exclusions (Fig. 1). The NODA cohort had a
greater proportion of metropolitan and non-academic
hospitals and borderline differences with respect to age,
race, T- stage and comorbidity scores.
From 2004 to 2010 (Period 1), the use of dose-escalated
radiation increased (p< 0.0001), even after adjusting for
potential confounders (Table 3). From 2010 to 2013
(Period 2), the use of dose-escalated radiation decreased
(p = 0.0018) (Table 4), even after adjusting for potential
confounders. Specifically, the percentage of patients
treated with dose-escalated radiation in the NODA in-
creased from 22% (95% CI: 15-31%) in 2004 to 37% in
2010 (95% CI: 31-43%) and then declined to 20% (95% CI:
13–28%) in 2012, its lowest level in the decade (Fig. 2).
Because RTOG 0617 was opened by 484 institutions
and accrued 544 patients, we sought to determine
whether accrual on to the trial itself might explain the
apparent change in patterns of care in the NODA
Table 2 Patient and hospital characteristics for the NODA
primary analytic cohort (excluding 2013 data) and the NCDB
cohort without RT dose exclusions
Study sample
characteristics




No. (%) No. (%)
Age
≤ 67 yo 829 (51.5) 12,619 (54.0) 0.05
> 67 yo 781 (48.5) 10,741 (46.0)
Sex
Male 943 (58.6) 13,422 (57.5) 0.38
Female 667 (41.4) 9938 (42.5)
Race
White 1395 (86.6) 19,841 (84.9) 0.03
Non-white 202 (12.5) 3377 (14.5)
Missing 13 (0.8) 142 (0.6)
Histology
Squamous 681 (42.3) 9680 (41.4) 0.50
Non-Squamous 929 (57.7) 13,680 (58.6)
T-stageb
T0-2 1074 (66.7) 15,418 (66.0) 0.06
T3 499 (31.0) 7942 (34.0)
Missing 37 (2.3) 0 (0%)
Charlson/Deyo Score
0 1063 (66.0) 14,695 (62.9) 0.03
1 400 (24.9) 6209 (26.6)
2+ 147 (9.1) 2456 (10.5)
Hospital typec
Community 1316 (81.7) 17,207 (73.7) <0.0001
Academic 294 (18.3) 6153 (26.3)
Hospital settingc
Metro 1338 (83.1) 17,204 (73.6) <0.0001
Non-metro 272 (16.9) 5210 (22.3)
Missing 0 (0) 946 (4.0)
aThe NODA cohort was defined by year of treatment start and the NCDB
cohort was defined by year of diagnosis. The NODA cohort was filtered using
RT dose criteria but the NCDB cohort was not in order to preserve its
representativeness of the national lung cancer population. *Chi-square test.
Missing data was excluded from Chi-Square comparison. bT –stage comparison
was done only for patients staged according to AJCC version 6 and missing
data was excluded from Chi-Square comparison. cHospital characteristics are
those of the diagnosing hospital, not treating institution
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dataset. Of the 499 patients treated with dose-escalated
radiation in the NODA dataset, only 20 (4%) patients
were treated to 74 Gy during the period in which the
high dose arms of RTOG 0617 were accruing.
An increasing utilization of dose-escalated radiation in
Period 1 and a decreasing utilization in Period 2 was
also observed in the NCDB 2004–2012 (Fig. 3, Tables 5
and 6). While the pattern of utilization was similar be-
tween the two datasets, the absolute estimates of
utilization were lower in the NCDB. In the NCDB
dataset, the percentage of patients treated with dose-
escalated radiation increased from 7% (95% CI: 6–8%) in
2004 to 12% (95% CI: 11-14%) in 2010 then decreased to
7% (95% CI: 6–9%) in 2012. The pattern of utilization of
low-standard dose radiation (≥59 and <64Gy) over time
was similar in the NODA and NCDB (Figs. 4 and 5, re-
spectively). In the NODA, the percentage of patients
treated using low-standard dose RT decreased from 47%
(95% CI: 37-56%) in 2004 to its lowest levels of 31%
(95% CI: 25–37%) in 2010 and then increased again to
44% (95%CI: 35-53%) in 2013. In the NCDB, the per-
centage of patients treated using low-standard dose
radiation decreased from 49% (95% CI: 46–52%) in
2004 to its lowest level of 31% (95% CI: 29-33%) in
Table 3 Logistic regression of dose escalation status and treatment year adjusting for potential confounders in NODA during
Period 1 (2004–2010)
NODA 2004–2010 (N = 1408)
Study sample characteristics Escalated dose Standard dose Escalated vs standard dose
No. (%) No. (%) Adjusted OR (95% CI) P*
Treatment year 1.16 (1.09–1.25) <0.0001
Age
≤ 67 yo 197 (52) 446 (49) ref
> 67 yo 181 (48) 466 (51) 0.92 (0.72–1.18) 0.52
Sex
Male 230 (61) 520 (57) ref
Female 148 (39) 392 (43) 0.82 (0.64–1.06) 0.14
Race
White 339 (90) 788 (86) ref
Non-white 37 (10) 115 (13) 0.61 (0.40–0.90) 0.01
Missing 2 (<1) 9 (1) Not included
Histology
Squamous 168 (44) 351 (38) ref
Non-Squamous 210 (56) 561 (62) 0.85 (0.66–1.10) 0.20
Derived AJCC v6 T-stage
T0-2 263 (70) 599 (66) ref
T3 110 (29) 282 (31) 0.87 (0.66–1.14) 0.30
Missing 5 (1) 31 (3) Not included
Charlson/Deyo Score
0 237 (63) 662 (68) ref
1 109 (29) 210 (24) 1.45 (1.09–1.93) 0.01
2+ 32 (8) 76 (8) 1.10 (0.69–1.73) 0.46
Hospital typea
Community 278 (74) 769 (84) ref
Academic 100 (26) 143 (16) 2.33 (1.70–3.20) <.0001
Hospital settinga
Metro 302 (80) 763 (84)
Non-metro 76 (20) 149 (16) 1.62 (1.16–2.24) 0.0046
*Chi-square test. Missing data was excluded from Chi-Square comparison. aHospital characteristics are those of the diagnosing hospital, not treating institution
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2010 and then increased again to 43% (95% CI: 41–
45%) in 2012.
Using a rolling three-year average and adjusting for
patient age and comorbidities, an increase in average
radiation dose would have been first detected in 2008
had the NODA network been monitoring radiation
dose in this lung cohort (2005–2007: 64.6 Gy, 95% CI
[64.4–65.3 Gy] vs 2008: 65.5 Gy 95% CI [65.1–66.3 Gy],
adjusted p = 0.0084) (Fig. 6). A decrease in average
radiation dose would have been first detected in 2012
(2009–2011: 65.6 Gy, 95% CI [65.3–66.0 Gy] vs 2012:
64.2 Gy 95% CI [63.4–65.0 Gy], adjusted p = 0.0004).
Discussion
Our analyses show that the use of dose-escalated
radiation (>70 Gy) in locally advanced NSCLCa in-
creased in the U.S. between 2004 and 2010. This
finding is consistent with our a priori hypothesis that
“radiation dose creep” occurred in the absence of
level I evidence, since no randomized comparisons of
standard versus dose-escalated radiation were formally
published over this period. Single-arm studies pub-
lished in the 2000s suggested that dose-escalation of
up to 74Gy in 2 Gy fractions was safe and effective
[10–13]. Questionnaire-based surveys show that the
Table 4 Logistic regression of dose escalation status and treatment year adjusting for potential confounders in NODA during
Period 2 (2010–2013)
NODA 2010–2013 (N = 567)
Study sample characteristics Escalated dose Standard dose Escalated vs standard dose
No. (%) No. (%) Adjusted OR (95% CI) P*
Treatment year 0.78 (0.66–0.91) 0.0018
Age
≤ 67 yo 112 (54) 239 (50) ref
> 67 yo 97 (46) 235 (50) 0.86 (0.61–1.21) 0.39
Sex
Male 129 (62) 274 (58) ref
Female 80 (38) 200 (42) 0.81 (0.57–1.14) 0.23
Race
White 181 (86) 394 (82) ref
Non-white 28 (13) 80 (17) 0.70 (0.42–1.12) 0.14
Missing 2 (1) 3 (1) Not included
Histology
Squamous 111 (53) 228 (48) ref
Non-Squamous 98 (47) 246 (52) 0.79 (0.56–1.12) 0.18
Derived AJCC v6 T-stage
T0-2 144 (69) 313 (66) ref
T3 65 (31) 154 (33) 0.88 (0.61–1.26) 0.49
Missing 0 (0) 7 (1) Not included
Charlson/Deyo Score
0 132 (63) 294 (62) ref
1 56 (27) 127 (27) 0.99 (0.67–1.46) 0.98
2+ 21 (10) 53 (11) 0.93 (0.52–1.61) 0.80
Hospital typea
Community 160 (77) 405 (85) ref
Academic 49 (23) 69 (15) 1.96 (1.27–3.49) 0.0047
Hospital settinga
Metro 174 (80) 412 (87) ref
Non-metro 35 (20) 62 (13) 2.07 (1.20–3.01) 0.0024
*Chi-square test. Missing data was excluded from Chi-Square comparison. aHospital characteristics are those of the diagnosing hospital, not treating institution
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evidence was compelling enough to already have chan-
ged practice by the mid-2000s, particularly for physi-
cians who considered themselves thoracic specialists
[14]. The use of escalating radiation doses in this co-
hort likely reflects in part disappointing local control
outcomes demonstrated with the standard of care.
When outcomes are poor, providers may be more open
to deviating from standards of care. Even after the
results of RTOG 0617 were communicated, it is clear
that the radiation oncology community did not fully re-
embrace the 60Gy treatment paradigm. While
utilization of doses >70Gy declined to its lowest levels
in 2012, our data suggests that less than half of patients
were treated using low-standard doses (≥59 Gy to <64Gy)
in 2012 and 2013. The perception that “more is better” ap-
pears to have persisted. Indeed, there is a growing interest
in whether intermediate doses (64Gy < dose <74 Gy)
might achieve the benefits of dose escalation without
the excess costs [15]. Of course, the complex inter-
play of hypoxic [16], immune [17] and other in vivo
responses to radiation and our limited understanding
of dose-response of normal tissues make the clinic ef-
fects of dose-escalation hard to predict and possibly
counter-intuitive.
We also observed that the use of dose-escalation
decreased between 2010 and 2013. The preliminary find-
ings of RTOG 0617 were first presented at the annual
meeting of ASTRO in 2011 [18]. The first peer-reviewed
manuscript was published in 2015 [4]. It is remarkable
that the rate of dose-escalation declined by 2012 to
levels observed in 2004, based on abstracts alone. In
some ways, the rapidity of response is re-assuring, but
Fig. 2 Percentage of locally advanced non-small cell lung cancer patients receiving dose-escalated RT (>70 Gy) over time from 2004 to 2013 in
the NODA. Period 1: 1/1/2004 to 12/31/2010. Period 2: 1/1/2010 to 12/31/2013. Bars represent 95% confidence interval
Fig. 3 Percentage of locally advanced non-small cell lung cancer
patients receiving dose-escalated RT (>70 Gy) over time from 2004
to 2012 in the NCDB. Period 1: 1/1/2004 to 12/31/2010. Period 2:
1/1/2010 to 12/31/2013. Bars represent 95% confidence interval
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raises the question: what would have been the conse-
quences of dose creep for these patients had RTOG
0617 been delayed or never performed?
Finally, we demonstrated that an increasing average
radiation dose in this cohort could have been de-
tected by 2008 within the smaller NODA network.
This result suggests that a national infrastructure for
monitoring cohort-specific radiation dosing patterns
already exists. Most centers in the U.S. now par-
ticipate in the CoC’s credentialing program so are
already abstracting information on radiation dose.
Thus, the CoC, SEER and many other programs that
aggregate cancer registry data internationally could feas-
ibly monitor dose to identify cohorts for which dose creep
is occurring. In addition, our demonstration used a
simple forecasting approach. More sophisticated ana-
lytical approaches could provide greater and timelier
information [19].
This study has important limitations. First, neither
the NODA nor the NCDB captures a statistically rep-
resentative portion of the U.S. cancer population. While
the NCDB captures approximately 70% of cancer cases,
diagnoses from small and rural facilities may be under-
represented. Second, the absolute estimates for the
Table 5 Logistic regression of dose escalation status and treatment year adjusting for potential confounders of the NCDB cohort
with RT dose exclusions during Period 1 (2004–2010)
NCDB 2004–2010 (N = 11,949)
Study sample characteristics Escalated dose Standard dose Escalated vs standard dose
No. (%) No. (%) Adjusted OR (95% CI) P*
Treatment year 1.11 (1.08–1.25) <0.0001
Age
≤ 67 yo 708 (57) 5856 (55) ref
> 67 yo 524 (43) 4861 (45) 0.89 (0.79–1.01) 0.07
Sex
Male 689 (56) 6223 (58) ref
Female 543 (44) 4494 (42) 1.10 (0.97–1.25) 0.12
Race
White 1062 (86) 9143 (85) ref
Non-white 162 (13) 1497 (14) 0.91 (0.76–1.09) 0.31
Missing 8 (1) 77 (1) Not included
Histology
Squamous 498 (40) 4333 (40) ref
Non-Squamous 734 (60) 6384 (60) 1.04 (0.89–1.15) 0.82
Derived AJCC v6 T-stage
T0-2 826 (67) 7286 (68) ref
T3 406 (33) 3431 (32) 1.03 (0.91–1.18) 0.60
Charlson/Deyo Score
0 786 (64) 6916 (64) ref
1 320 (26) 2778 (64) 0.98 (0.85–1.13) 0.81
2+ 126 (10) 1023 (10) 1.05 (0.85–1.29) 0.64
Hospital typea
Community 901 (73) 7991 (75) ref
Academic 331 (27) 2726 (25) 1.09 (0.95–1.25) 0.23
Hospital settinga
Metro 904 (73.4) 7777 (73) ref
Non-metro 274 (22.2) 2476 (23) 0.96 (0.83–1.11) 0.59
Missing 54 (4.4) 464 (4) Not included
*Chi-square test. Missing data was excluded from Chi-Square comparison. aHospital characteristics are those of the diagnosing hospital, not treating institution
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utilization of dose-escalated therapy varied between the
NODA and the NCDB analyses. In contrast, the NODA
and the NCDB generated similar estimates for the
utilization of low-standard dose over the same time
period. This discrepancy may reflect differences in the
characteristics of the institutions represented within each
dataset and challenges that registrars have in interpreting
radiation summaries of patients who have both a regional
and a boost treatment, which is more common in patients
receiving dose-escalated therapy. The NODA likely con-
tains more accurate dose data, but it lacks the representa-
tiveness of the NCDB. Given that the NODA and NCDB
have complementary strengths and weaknesses, the true
absolute utilization rate of dose-escalation therapy over
this period probably falls somewhere between the NODA
and NCDB estimates. Third, our analyses do not adjust
for radiation technique (e.g., 3D conformal vs IMRT).
While the NCDB does have a field identifying “treatment
modality”, the current options eligible for cancer registrars
are not mutually exclusive. For example, a registrar can
identify a treatment as 6MV photons or IMRT, though
often a treatment is both. Because of this issue, we chose
not to include this variable in our analyses. While
Table 6 Logistic regression of dose escalation status and
treatment year adjusting for potential confounders of the NCDB
cohort with RT dose exclusions during Period 2 (2010–2012)







Escalated vs standard dose
No. (%) No. (%) Adjusted OR (95% CI) P*
Treatment year 0.77 (0.69–0.85) <0.0001
Age
≤ 67 yo 367 (54) 3124 (53) ref
> 67 yo 308 (46) 2747 (47) 0.93 (0.79–1.09) 0.38
Sex
Male 393 (58) 3308 (56) ref
Female 282 (42) 2563 (44) 0.94 (0.79–1.11) 0.45
Race
White 594 (88) 4937 (84) ref
Non-white 78 (12) 895 (15) 0.76 (0.59–0.98) 0.04
Missing 3 (<1) 39 (1) Not included
Histology
Squamous 315 (47) 2658 (45) ref
Non-Squamous 360 (53) 3213 (55) 0.97 (0.82–1.14) 0.72
Derived AJCC v6 T-stage
T0-2 425 (63) 3693 (63) ref
T3 250 (37) 2178 (37) 1.01 (0.85–1.19) 0.95
Charlson/Deyo Score
0 406 (60) 3510 (60) ref 0.80
1 196 (29) 1684 (29) 1.00 (0.83–1.20) 0.83
2+ 73 (11) 677 (11) 0.96 (0.73–1.24)
Hospital typea
Community 520 (77) 4220 (72) ref
Academic 155 (23) 1651 (28) 0.80 (0.66–0.97) 0.02
Hospital settinga
Metro 495 (73) 4421 (75) ref
Non-metro 163 (24) 1285 (22) 1.07 (0.88–1.29) 0.51
Missing 17 (3) 165 (3) Not included
*Chi-square test. Missing data was excluded from Chi-Square comparison.
aHospital characteristics are those of the diagnosing hospital, not
treating institution
Fig. 4 Percentage of locally advanced non-small cell lung cancer
patients receiving low-standard dose radiation (<64 Gy) over time from
2004 to 2013 in the NODA. Period 1: 1/1/2004 to 12/31/2010. Period 2:
1/1/2010 to 12/31/2013. Bars represent 95% confidence interval
Fig. 5 Percentage of locally advanced non-small cell lung cancer
patients receiving low-standard dose radiation (<64 Gy) over time from
2004 to 2012 in the NCDB. Period 1: 1/1/2004 to 12/31/2010. Period 2:
1/1/2010 to 12/31/2013. Bars represent 95% confidence interval
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increasing adoption of IMRT may in part explain the
increasing utilization of dose-escalated radiation
observed before 2011, it would not explain the decline
after 2011.
Conclusion
Patterns of radiation dosing in locally advanced NSCLCa
changed in the U.S. from 2004 to 2013 and in the ab-
sence of level 1 evidence. These changes could have
been identified using a simple radiation dose monitoring
approach that uses data already aggregated from most
cancer centers in the U.S.
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